文献速递乳腺癌放疗

乳腺癌大分割区域淋巴结照射剂量递增的毒性评估:一项回顾性研究

Toxicity Evaluation of Dose-Escalation in Hypofractionated Regional Nodal Irradiation for Breast Cancer: A Retrospective Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-04-15

该回顾性研究分析2015年3月至2017年2月接受大分割区域淋巴结照射的381例乳腺癌患者,比较标准剂量与剂量递增组的毒性。剂量递增组淋巴水肿(32.1% vs 14.8%,OR 2.72,P=0.0004)和肩部僵硬(23.8% vs 9.4%,OR 2.01,P=0.0205)发生率显著更高。作者认为需密切监测和及时康复干预。

要点

  • 剂量递增组淋巴水肿发生率32.1%,标准剂量组14.8%(OR 2.72,P=0.0004)。
  • 剂量递增组肩部僵硬发生率23.8%,标准剂量组9.4%(OR 2.01,P=0.0205)。
  • 剂量递增有增加淋巴水肿和肩部僵硬严重程度的趋势。

核心结论

  • 接受大分割区域淋巴结照射剂量递增的乳腺癌患者,淋巴水肿和肩部僵硬风险高于标准剂量组。
  • 作者认为对这些患者实施密切频繁监测以早期发现并及时康复干预至关重要。

研究设计与样本

  • 回顾性分析2015年3月至2017年2月接受大分割区域淋巴结照射的381例乳腺癌患者。
  • 患者接受区域淋巴结区标准剂量43.2 Gy/16次(48.7 Gy3.5等效剂量,α/β=3.5 Gy的2 Gy等效剂量)或剂量递增中位剂量54.8 Gy3.5等效剂量(范围51.7-60.9 Gy3.5等效剂量),取决于临床和病理淋巴结分期。
  • 评估淋巴水肿和肩部僵硬的毒性发生率,并进行统计分析以识别相关因素。

主要发现

  • 中位随访时间32.3个月(范围5.7-47.0个月)。
  • 放疗后71例(18.6%)患者发生淋巴水肿,48例(12.6%)发生肩部僵硬。
  • 剂量递增组淋巴水肿发生率32.1%,标准剂量组14.8%(OR 2.72,P=0.0004)。
  • 剂量递增组肩部僵硬发生率23.8%,标准剂量组9.4%(OR 2.01,P=0.0205)。
  • 剂量递增有增加淋巴水肿和肩部僵硬严重程度的趋势。

临床怎么用

  • 作者认为对接受大分割区域淋巴结照射剂量递增的患者,实施密切频繁监测以早期发现并及时康复干预至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Regional nodal irradiation (RNI) to the axilla and supraclavicular area presents distinct toxicities, such as lymphedema and shoulder stiffness, compared with whole-breast irradiation. There is insufficient evidence on the safety of dose-escalation in hypofractionated RNI. We aimed to evaluate and compare toxicity rates in patients with breast cancer who received hypofractionated RNI with and without dose-escalation. METHODS AND MATERIALS: We retrospectively analyzed 381 patients with breast cancer treated with hypofractionated RNI between March 2015 and February 2017. Patients received either the standard-dose to the regional nodal area (43.2 Gy/16 fx; 48.7 Gy3.5 equivalent dose [EQD2], 2 Gy equivalent dose with α/β= 3.5 Gy) or dose-escalation with a median dose of 54.8 Gy3.5 EQD2 (range, 51.7-60.9 Gy3.5 EQD2), depending on clinical and pathologic nodal stage. Toxicity rates of lymphedema and shoulder stiffness were assessed, and statistical analyses were conducted to identify associated factors. RESULTS: The median follow-up time was 32.3 months (5.7-47.0 months). After radiation therapy, 71 (18.6%) patients developed lymphedema, and 48 (12.6%) developed shoulder stiffness. Patients who received dose-escalation exhibited significantly higher rates of lymphedema (32.1% vs 14.8%; odds ratio, 2.72, P = .0004) and shoulder stiffness (23.8% vs 9.4%; odds ratio, 2.01, P = .0205) compared with the standard-dose group. Moreover, dose-escalation showed a tendency to increase the severity of lymphedema and shoulder stiffness. CONCLUSIONS: Patients who received dose-escalation in hypofractionated RNI face a higher risk of developing lymphedema and shoulder stiffness compared with those who received standard-dose hypofractionated RNI. Therefore, it is crucial to implement close and frequent monitoring for early detection, along with timely rehabilitation interventions for these patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim E, Yoo JS, Kim YJ, et al. Toxicity Evaluation of Dose-Escalation in Hypofractionated Regional Nodal Irradiation for Breast Cancer: A Retrospective Study. Int J Radiat Oncol Biol Phys. 2024. PMID: 38631540. doi:10.1016/j.ijrobp.2024.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。